V

Vistin Pharma ASA
OSE:VISTN

Watchlist Manager
Vistin Pharma ASA
OSE:VISTN
Watchlist
Price: 24.2 NOK -2.02% Market Closed
Market Cap: 1.1B NOK
Have any thoughts about
Vistin Pharma ASA?
Write Note

Relative Value

The Relative Value of one VISTN stock under the Base Case scenario is 27.4 NOK. Compared to the current market price of 24.2 NOK, Vistin Pharma ASA is Undervalued by 12%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VISTN Relative Value
Base Case
27.4 NOK
Undervaluation 12%
Relative Value
Price
V
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
46
vs Industry
50
Median 3Y
2.6
Median 5Y
2.6
Industry
2.6
vs History
50
vs Industry
27
Median 3Y
22.1
Median 5Y
17.3
Industry
23
vs History
23
vs Industry
31
Median 3Y
12.9
Median 5Y
11.6
Industry
17.8
vs History
7
vs Industry
20
Median 3Y
22.8
Median 5Y
-5.2
Industry
25.4
vs History
4
vs Industry
25
Median 3Y
3.2
Median 5Y
3.1
Industry
2.2
vs History
38
vs Industry
46
Median 3Y
2.6
Median 5Y
2.6
Industry
2.8
vs History
42
vs Industry
51
Median 3Y
4.5
Median 5Y
4.3
Industry
5.4
vs History
55
vs Industry
32
Median 3Y
12.7
Median 5Y
12.7
Industry
13.7
vs History
52
vs Industry
32
Median 3Y
14.3
Median 5Y
14.9
Industry
17.2
vs History
17
vs Industry
31
Median 3Y
13
Median 5Y
5.2
Industry
16.5
vs History
9
vs Industry
17
Median 3Y
13.9
Median 5Y
-3.8
Industry
19.3
vs History
15
vs Industry
30
Median 3Y
2.7
Median 5Y
2.7
Industry
2

Multiples Across Competitors

VISTN Competitors Multiples
Vistin Pharma ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Vistin Pharma ASA
OSE:VISTN
1.1B NOK 2.5 15.7 11.1 13.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.4B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 169.3 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
NO
V
Vistin Pharma ASA
OSE:VISTN
Average P/E: 30.9
15.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top